# US 2025/0152677 A1 · Treatment of liver cancers by disrupting the beta-catenin/tcf-4 binding site located upstreatm of meg3 in the dlk1/dio3 locus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152677 A1
- Document ID: US20250152677A1
- Status: Published application
- Kind: A1
- Application number: 18/835,868
- Filed: 2023-02-13
- Published: 2025-05-15
- Earliest claimed: 2022-02-14
- Assignees: Institut National de la Sante et de la Recherche Medicale; Université Paris Cité; Sorbonne Universite; Centre National De La Recherche Scientifique; Inovarion
- Applicants: Institut National De La Santé Et De La Recherche MéDicale; Université Paris Cité; Sorbonne Université; Centre National De La Recherche Scientifique; Inovarion
- Inventors: Angélique GOUGELET; Julie SANCEAU; Lucie POUPEL; Sabine COLNOT
- Web page: https://patentgrep.com/patent/US20250152677A1

## CPC

- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- A61P 35/00: Antineoplastic agents
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/86: Viral vectors
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2320/30: Special therapeutic applications
- C12N 2330/51: Specially adapted vectors
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Activating mutations in CTNNB1 gene encoding β-catenin is encountered in approximately 30% of hepatocellular carcinoma (HCC) and in more than 80% of hepatoblastoma. In ApcΔhep model, the inventors unravel the biggest cluster of non-coding RNAs identified called the DLK1/DIO3 locus as the most significantly induced region in response to β-catenin activation regarding transcription of coding and non-coding elements. Using in vivo Crispr/cas9 strategy, the inventors were able to demonstrate that β-catenin and its cofactor TCF-4 directly bind on a WRE-containing site located upstream of Meg3 to create an active enhancer regulatory region engaged in chromatin remodeling in the direct vicinity of this binding site but also at distance by long range DNA-DNA contacts to promote transcription of the entire locus. These Crispr/cas9 constructs have also proved to be a valuable strategy to impair the locus expression in the murine models mimicking HCC and hepatoblastoma (ApcΔhep and β-cateninΔExon3 tumors) but also in two cell lines with activating mutations in β-catenin encoding gene, the murine Hepa1-6 and human HuH6 cells. In transformed cells, it significantly impaired cell proliferation in vitro and HuH6 sternness capacities but also tumor progression in Hepa1-6 allografts. In mouse models, the locus editing during early steps of tumorigenesis decreased the proliferation of ApcΔhep preneoplastic hepatocytes but also those of ApcΔhep and β-cateninΔExon3 tumor cell resulting in impairment of tumor size. In conclusion, the results demonstrate that disrupting the β-catenin/TCF-4 binding site located upstream of Meg3 in the DLK1/DIO3 locus represents a very interesting approach for the treatment of liver cancers.

## Claims

### Claim 1

A method of treating a liver cancer in a patient harbouring at least one activating mutation in CTNNB1 gene comprising administering to the patient an agent capable of disrupting a b-catenin/TCF-4 binding site located upstream of Meg3 in a DLK1/DIO3 locus.

### Claim 2 (depends on 1)

The method of claim 1 wherein the agent is a DNA-targeting endonuclease that cleaves genomic DNA of cancer cells in at least one position of the b-catenin/TCF-4 binding site, thereby repressing transcription of the DLK1/DIO3 locus.

### Claim 3 (depends on 2)

The method of claim 2, wherein the cleavage of the genomic DNA leads to genome editing of the b-catenin/TCF-4 binding site located upstream of Meg3 and prevents binding of a transcriptional b-catenin/TCF-4 complex to its binding site.

### Claim 4 (depends on 1)

The method of claim 1, wherein the patient suffers from a hepatocellular carcinoma or from a hepatoblastoma.

### Claim 5 (depends on 2)

The method of claim 2, wherein the DNA targeting endonuclease is a TALEN.

### Claim 6 (depends on 2)

The method of claim 2, wherein the DNA targeting endonuclease is a ZFN.

### Claim 7 (depends on 2)

The method of claim 2, wherein the DNA targeting endonuclease is a CRISPR-associated endonuclease.

### Claim 8 (depends on 7)

The method of claim 7 wherein the CRISPR-associated endonuclease is a Cas9 nuclease.

### Claim 9 (depends on 7)

The method of claim 7 further comprising administering an effective amount of one or more guide RNA(s) with the CRISPR-associated endonuclease.

### Claim 10 (depends on 9)

The method of claim 9 wherein the one or more guide RNAs recruits the CRISPR-associated endonuclease to the b-catenin/TCF-4 binding site located upstream of Meg3 thereby generating DNA double-strand breaks (DSBs).

### Claim 11 (depends on 9)

The method of claim 9 wherein a combination of a first and a second guide RNA is administered and wherein the first guide RNA targets the sequence SEQ ID NO:4 and the second guide RNA targets at least one sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:5 and SEQ ID NO:6.

### Claim 12 (depends on 9)

The method of claim 9 wherein a combination of a first and a second guide RNA is administered and wherein the first guide RNA is encoded by SEQ ID NO:8 and the second guide RNA is encoded by a sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:9, and SEQ ID NO: 10.

### Claim 13 (depends on 9)

The method of claim 9 wherein the CRISPR-associated endonuclease and the one or more guide RNAs are expressed from one or more vectors.

### Claim 14 (depends on 13)

The method of claim 13 wherein the CRISPR endonuclease and the one or more guide RNAs are encoded by the same nucleic acid.

### Claim 15 (depends on 13)

The method of claim 13 wherein the one or more vectors is a viral vector.

### Claim 16 (depends on 15)

The method of claim 15 wherein the viral vector is an adeno-associated virus (AAV) vector.

### Claim 17 (depends on 16)

The method of claim 16, wherein the AAV vector is an AAV8 vector.

### Claim 18 (depends on 17)

The method of claim 17, wherein the AAV8 vector is an AAV2/AAV8 vector.
